Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Surrozen will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ophthalmology programs including development of new treatment options for retinopathies. Other ...
Clinical Trials Arena on MSN6d
Surrozen drops hepatitis drug after Phase I flop
Surrozen said despite SZN-043 demonstrating changes in liver function assays, there was not enough clinical benefit for ...
Nasdaq7d
Surrozen, Inc. Prioritizes Ophthalmology Pipeline with $175 Million Financing and Discontinues SZN-043 Development
Wholly-Owned Ophthalmology Portfolio SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment ...
Surrozen to discontinue development of SZN-043 in alcohol associated hepatitis
The Company will discontinue development of SZN-043 in severe alcohol associated hepatitis. While treatment with SZN-043 was safe and ...
Buffalo Rising3y
SZN sets up shop at Kenmore Kitchens
Kenmore Kitchens is awaiting your arrival. Kenmore Kitchens is bursting with flavor with Buffalo’s first large scale ghost kitchen set up, and SZN had just joined in on the party. Alongside ...